Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Annette R. Zampelli"'
Publikováno v:
The Nurse Practitioner. 40:1-7
Primary care providers (PCPs) play a key role in identifying patients with primary immunodeficiency diseases (PIDDs). This diagnosis has implications for PCPs, as patients continue to require primary care and management after a PIDD diagnosis has bee
Publikováno v:
Journal of Infusion Nursing. 36:384-390
A number of ancillary supplies are used in the process of administering subcutaneous immunoglobulin. The particular type of ancillary supplies used (needles, tubing, and tape) may contribute to the development of issues at the local infusion site. Pa
Autor:
Annette R. Zampelli
Publikováno v:
Home Health Care Management & Practice. 19:431-435
Pediatric patients diagnosed with primary antibody deficiencies often require lifelong immune globulin replacement to help protect them from life-threatening infections. Although this is not a cure or a treatment for the disorder, replacement therapy
Autor:
Bettina C, Hilman, Annette R, Zampelli
Publikováno v:
The Journal of asthma : official journal of the Association for the Care of Asthma.
Publikováno v:
Journal of Allergy and Clinical Immunology. 133:AB10
Publikováno v:
Journal of Allergy and Clinical Immunology. 133:AB146
Publikováno v:
Journal of Allergy and Clinical Immunology. 131:AB49
Publikováno v:
Journal of Allergy and Clinical Immunology. 131:AB69
S U N D A Y 247 Late Onset Invasive Pneumococcal Disease in a Patient with IRAK4 Deficiency Michael David O’Sullivan, Catherine Stroud, Mario Abinun, Rainer Doffinger, Steven O’Reilly, Marzena Ciechomska, Dawn Barge, Rebecca Treacy, Stephen Owens
Publikováno v:
Neurology. 78:P07.217-P07.217
Objective: To report the use of 20% proline-stabilized subcutaneous immunoglobulin (SCIG; Hizentra®) in 2 patients with myasthenia gravis (MG) and 1 patient with chronic inflammatory demyelinating polyneuropathy (CIDP) for whom intravenous immunoglo
Publikováno v:
Journal of Allergy and Clinical Immunology. 129:AB56
Increased use of specialized infusion therapies has necessitated training of health care providers and patients. The Starting Hizentra Administration with Resources and Education (SHARE) program provided 709 US participants with information to educat